(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
-0.91% $ 5.44
@ $6.07
Emitido: 13 feb 2024 @ 15:46
Retorno: -10.38%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: -2.10 %
Live Chart Being Loaded With Signals
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases...
Stats | |
---|---|
Volumen de hoy | 529 526 |
Volumen promedio | 600 068 |
Capitalización de mercado | 524.33M |
EPS | $0 ( 2024-05-09 ) |
Próxima fecha de ganancias | ( $-0.500 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.91 |
ATR14 | $0.00700 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 500 000 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Buy | 98 533 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 98 533 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 41 250 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 19 420 | Stock Option (right to buy) |
INSIDER POWER |
---|
-25.53 |
Last 100 transactions |
Buy: 2 784 515 | Sell: 4 159 752 |
Volumen Correlación
Alector Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
AEHR | 0.894 |
NEOG | 0.893 |
VMAR | 0.891 |
BROG | 0.89 |
EHTH | 0.889 |
LCID | 0.885 |
EVOK | 0.876 |
RVNC | 0.876 |
NDRA | 0.874 |
TXG | 0.871 |
10 Correlaciones Más Negativas | |
---|---|
BSCO | -0.847 |
ESTA | -0.83 |
NESR | -0.823 |
OXSQ | -0.82 |
PTMN | -0.817 |
LPCN | -0.811 |
SFBC | -0.81 |
KRUS | -0.808 |
IMPP | -0.805 |
AEAE | -0.802 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alector Inc Correlación - Moneda/Commodity
Alector Inc Finanzas
Annual | 2023 |
Ingresos: | $97.06M |
Beneficio Bruto: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2023 |
Ingresos: | $97.06M |
Beneficio Bruto: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2022 |
Ingresos: | $133.62M |
Beneficio Bruto: | $125.15M (93.66 %) |
EPS: | $-1.620 |
FY | 2021 |
Ingresos: | $207.09M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.467 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico